Tag Archives: generic biologicals

“Obamacare” Survives – Including Path to Generic Biologicals

Biotech patent attorneys rejoice – no matter if you represent generic companies or NDA holders,  the 5-4 decision of the Supreme Court upholding the “individual mandate” – not under the commerce clause, but as an appropriate use of Congress’ power to … Continue reading

Posted in Follow-On Biologics | Tagged , , , , , , , | Leave a comment